ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients

Journal of Alzheimer's Disease

Volumn 22, Issue 1, 2010, Pages 119-128

  Steinacker, Petra ^a   Klafki, Hans ^b   Lehnert, Stefan ^a   Jesse, Sarah ^a   V Arnim, Christine A F ^a   Tumani, Hayrettin ^a   Pabst, Alice ^a   Kretzschmar, Hans A ^c   Wiltfang, Jens ^b   Otto, Markus ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer's disease; biomarker; cerebrospinal fluid; Creutzfeldt Jakob disease; duplex electrochemiluminescence assay; extracellular signal regulated kinase ERK1 2

Indexed keywords

BIOCHEMICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN 14 3 3; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROCHEMILUMINESCENCE ASSAY; ELECTROCHEMISTRY; FEMALE; HUMAN; MALE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 78650671552     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100030     Document Type: Article

References (40)

1. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J (1996) Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 53, 913-920.
2. Bieschke J, Giese A, Schulz-Schaeffer W, Zerr I, Poser S, Eigen M, Kretzschmar H (2000) Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proc Natl Acad Sci USA 97, 5468-5473.
3. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG (1996) The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335, 924-930.
4. Organisation WH, (1998) Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies. Emerging and Other Communicable Diseases, Surveillance and Control, 1-26.
5. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ, Jr. (2000) An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 48, 395-398.
6. Satoh K, Shirabe S, Eguchi H, Tsujino A, Eguchi K, Satoh A, Tsujihata M, Niwa M, Katamine S, Kurihara S, Matsuo H (2006) 14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease and neurodegenerative disease in Japan. Cell Mol Neurobiol 26, 45-52.
7. Bartosik-Psujek H, Archelos JJ (2004) Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 251, 414-420.
8. Siman R, Roberts VL, McNeil E, Dang A, Bavaria JE, Ram-chandren S, McGarvey M (2008) Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest. Brain Res 1213, 1-11.
9. Saiz A, Graus F, Dalmau J, Pifarre A, Marin C, Tolosa E (1999) Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol 46, 774-777.
10. Green AJ, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod MA, Ironside JW, Will RG, Knight RS (2001) Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 70, 744-748.
11. Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58, 192-197. (Pubitemid 34084207)
12. Cepek L, Steinacker P, Mollenhauer B, Wiese B, Ciesielczyk B, Bibl M, Wiltfang J, Zerr I, Schulz-Schaeffer W, Kret-zschmar HA, Poser S, Otto M (2005) Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 19, 376-382. (Pubitemid 40663335)
13. Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M (2004) Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 370, 36-39.
14. Van Everbroeck B, Green AJ, Pals P, Martin JJ, Cras P (1999) Decreased Levels of Amyloid-beta 1-42 in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients. J Alzheimers Dis 1, 419-424.
15. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M (2003) Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 54, 263-267.
16. Beaudry P, Cohen P, Brandel JP, Delasnerie-Laupretre N, Richard S, Launay JM, Laplanche JL (1999) 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geri-atr Cogn Disord 10, 40-46.
17. Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, Poser S, Kretzschmar HA, Mader M, Weber T (1997) S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 244, 566-570. (Pubitemid 27464102)
18. Jesse S, Steinacker P, Cepek L, von Arnim CA, Tumani H, Lehnert S, Kretzschmar HA, Baier M, Otto M (2009) Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. J Alzheimers Dis 17, 541-551.
19. Steinacker P, Rist W, Swiatek-de-Lange M, Lehnert S, Jesse S, Pabst A, Tumani H, von Arnim CA, Mitrova E, Kretzschmar HA, Lenter M, Wiltfang J, Otto M (2010) Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease. Proteomics 10, 81-89.
20. Steinacker P, Schwarz P, Reim K, Brechlin P, Jahn O, Kratzin H, Aitken A, Wiltfang J, Aguzzi A, Bahn E, Baxter HC, Brose N, Otto M (2005) Unchanged survival rates of 14-3-3gamma knockout mice after inoculation with pathological prion protein. Mol Cell Biol 25, 1339-1346.
21. Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, Rossor M, Rudge P, Siddique D, Spyer M, Thomas D, Walker S, Webb T, Wroe S, Darbyshire J (2009) Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 8, 334-344.
22. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wilt-fang J, Irle E, Pergande G, Ellers-Lenz B, Windl O, Kret-zschmar HA, Poser S, Prange H (2004) Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 62, 714-718.
23. Klafki HW, Lewczuk P, Kamrowski-Kruck H, Maler JM, Muller K, Peters O, Heuser I, Jessen F, Popp J, Frolich L, Wolf S, Prinz B, Luckhaus C, Schroder J, Pantel J, Gertz HJ, Kolsch H, Muller BW, Esselmann H, Bibl M, Kornhuber J, Wiltfang J (2009) Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated for. J Alzheimers Dis 18, 613-622.
24. Lee HP, Jun YC, Choi JK, Kim JI, Carp RI, Kim YS (2005) Activation of mitogen-activated protein kinases in hamster brains infected with 263K scrapie agent. J Neurochem 95, 584-593.
25. WHO (1998) Consensus on criteria for sporadic CJD. Geneve.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
27. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
28. Steinacker P, Hawlik A, Lehnert S, Jahn O, Meier S, Gorz E, Braunstein KE, Krzovska M, Schwalenstocker B, Jesse S, Propper C, Bockers T, Ludolph A, Otto M (2009) Neuroprotective function of cellular prion protein in a mouse model of amyotrophic lateral sclerosis. Am J Pathol 176, 1409-1420.
29. Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF (2001) CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 56, 1528-1533.
30. Huang N, Marie SK, Livramento JA, Chammas R, Nitrini R (2003) 14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology 61, 354-357.
31. Chiarini LB, Freitas AR, Zanata SM, Brentani RR, Martins VR, Linden R (2002) Cellular prion protein transduces neuro-protective signals. EMBOJ 21, 3317-3326.
32. Toni M, Spisni E, Griffoni C, Santi S, Riccio M, Lenaz P, Tomasi V (2006) Cellular prion protein and caveolin-1 interaction in a neuronal cell line precedes fyn/erk 1/2 signal transduction. J Biomed Biotechnol 2006, 69469.
33. Nordstrom E, Fisone G, Kristensson K (2009) Opposing effects of ERK and p38-JNK MAP kinase pathways on formation of prions in GT1-1 cells. FASEB J 23, 613-622.
34. Nordstrom EK, Luhr KM, Ibanez C, Kristensson K (2005) Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc. J Neurosci 25, 8451-8456.
35. Pamplona R, Naudi A, Gavin R, Pastrana MA, Sajnani G, Ilieva EV, Del Rio JA, Portero-Otin M, Ferrer I, Requena JR (2008) Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radic Biol Med 45, 1159-1166.
36. LaCasse RA, Striebel JF, Favara C, Kercher L, Chesebro B (2008) Role of Erk1/2 activation in prion disease pathogenesis:absence of CCR1 leads to increased Erk1/2 activation and accelerated disease progression. JNeuroimmunol 196, 16-26.
37. Uppington KM, Brown DR (2008) Resistance of cell lines to prion toxicity aided by phospho-ERK expression. J Neurochem 105, 842-852.
38. Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, Grundke-Iqbal I (2002) Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res 109, 45-55.
39. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AK, Holbrook N, Siedlak SL, Harris PL, Smith MA (1999) Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10, 2411-2415.
40. Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, Forstl H, Kurz A (2003) Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 8, 343-347.